Abstract 5187
Background
The practice of oncology is challenging, especially when dealing with terminally ill patients and end of life. This is not without an emotional impact on oncologists, with potential negative effect on patient care and personal lives. We aimed to outline the main factors that makes of patients’ death an emotionally difficult experience, and to identify practical coping strategies.
Methods
An online survey was completed by 128 oncologists from three North African countries and France, on March-April 2019. All surveys were anonymous and confidential. The questionnaire included socio-demographic information, and sections about patients’ death and coping strategies.
Results
Most respondents were female (83.5%) and young oncologists (20-40 years-old), with less than 10 years professional experience (85.3%), but seeing more than 50 patients per week, and experiencing 0-2 deaths per month. They were mostly from Tunisia (n = 99), Morocco (n = 25), Algeria (n = 2) and France (n = 2). The majority was medical oncologists (57.9%), then radiation oncologists (29.4%). More than two-thirds of the oncologists reported that young age, long-term relationship and family denial towards the prognosis were the main factors making death or therapeutic failure announcement the most difficult. Unexpected evolution leading to death, and the non-access to more effective treatment in our countries had an emotional impact on 70% of the oncologists. A variety of coping strategies was identified: mainly peer support from colleagues and/or family and friends (53.5%), practicing hobbies (39.4%), seeking support in praying and faith (26.3%). Addictive behavior and/or medications were reported in 9.1%, significantly in single respondents (p 0.051). A majority (n = 83) reported a change in their character noticed by their families since the practice of oncology. The oncologists expressed becoming better able to set priorities (48%), more humble and human (61.4%) and motivated to improve their quality of health care (33.9%).
Conclusions
Dealing with patients’ death and confronting therapeutic failure have obviously an effect on oncologists’ personal life. We need to be aware of this issue, and to propose different coping strategies and interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5553 - Cytokine genetic variations and worse quality of life among family caregivers of head and neck cancer patients in palliative care
Presenter: Daniel Pequeno
Session: Poster Display session 1
Resources:
Abstract
4321 - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: a matched cohort study
Presenter: Annelies Boekhout
Session: Poster Display session 1
Resources:
Abstract
779 - Capecitabine vs Cisplatin along with concurrent radiotherapy in the treatment of inoperable lower esophageal cancers focusing on TWISTT score and QOL
Presenter: Goutham Anugu
Session: Poster Display session 1
Resources:
Abstract
5914 - Cancer, Mental Health and End Life Simulation (CAMhELS): A novel effectiveness evaluation.
Presenter: Asanga Fernando
Session: Poster Display session 1
Resources:
Abstract
2597 - Cancer patients’ expectations and understanding about their disease
Presenter: Mónica Pinho
Session: Poster Display session 1
Resources:
Abstract
4579 - Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Presenter: Andrea Sbrana
Session: Poster Display session 1
Resources:
Abstract
5058 - Preparedness for caregiving in caregivers of cancer patients
Presenter: Hatice Yakar
Session: Poster Display session 1
Resources:
Abstract
5917 - Oncologic Emergency Medicine in the real world: A survey and proposal for improvement
Presenter: Carintia Dorta Pérez
Session: Poster Display session 1
Resources:
Abstract
4077 - The Reality of Critical Cancer Patients in a Polyvalent Intensive Care Unit
Presenter: Tiago Filipe Da Cruz Tomas
Session: Poster Display session 1
Resources:
Abstract
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract